{
    "nct_id": "NCT06807619",
    "official_title": "BrainMet ADePPT (Anticancer Drug Penetration Platform Trial)",
    "inclusion_criteria": "* Adult patients ≥ 18 years of age with one or more brain tumors planned for neurosurgical resection/biopsy\n* Patients with concomitant leptomeningeal metastasis are eligible provided they have parenchymal brain neoplastic disease requiring resection/biopsy\n* For all cohorts: no limit on prior CNS radiation or systemic therapyKPS ≥ 60\n* Life expectancy >12 weeks\n* Adequate treatment washout period from prior therapies to allow recovery from any prior treatment-related toxicities before enrollment in the judgment of the Investigator\n* Adequate bone marrow, renal, hepatic, and coagulation parameters (obtained ≤7 days prior to the first day of study treatment):\n\n  * Absolute neutrophil count (ANC) ≥1.0 × 10^3/μL (granulocyte-colony stimulating factor administration is not allowed within 1 week prior to C1D1)\n  * Platelet count ≥10.0x10^4/μL. Note: Participants requiring ongoing transfusions or growth factor support to maintain platelet count ≥10.0x10^4/μL are not eligible. (Platelet transfusion is not allowed within 1 week prior to C1D1)\n  * Hemoglobin ≥ 7.0 g/dL (≥ 8 g/dL in gastric cancer / gastroesophageal cancer indications). Note: Participants requiring ongoing transfusions or growth factor support to maintain hemoglobin ≥8.0 g/dL are not eligible (Red blood cell transfusion is not allowed within 1 week prior to C1D1)\n  * Creatinine clearance ≥30 mL/min, as calculated using the Cockcroft-Gault equation\n  * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × upper limit of normal (ULN) (<5x ULN in participants with liver metastases)\n  * Total bilirubin ≤1.5 × ULN) if no liver metastases or <3 × ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known allergy or hypersensitivity to study treatment or any of the study drug excipients. For patients who are allergic to gadolinium-based agents may receive premedication as per institutional protocol or imaged without contrast at the discretion of the Principal Investigator; reactions will be managed per standard institutional protocol\n* Multiple primary malignancies within 3 years, with the exception of:\n\n  * adequately resected non-melanoma skin cancer\n  * carcinoma in situ of the cervix\n  * Smoldering pre-malignant or malignant conditions with minimal concern for CNS or extracranial progression during treatment such as CLL or MGUS based on the assessment of the treating provider\n  * curatively treated in-situ disease\n  * other solid tumors curatively treated\n  * for patients with metastatic breast cancer: contralateral breast cancer",
    "miscellaneous_criteria": ""
}